Orchestra BioMed
OBIO
OBIO
39 hedge funds and large institutions have $75.5M invested in Orchestra BioMed in 2023 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
1.08% less ownership
Funds ownership: 31.24% → 30.16% (-1.1%)
61% less capital invested
Capital invested by funds: $193M → $75.5M (-$118M)
Holders
39
Holding in Top 10
2
Calls
–
Puts
–
Top Buyers
| 1 | +$3.51M | |
| 2 | +$1.06M | |
| 3 | +$754K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$616K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$488K |
Top Sellers
| 1 | -$1.58M | |
| 2 | -$1.18M | |
| 3 | -$568K | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$232K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$196K |